aripiprazole indications/contra

Stem definitionDrug idCAS RN
psychotropics, phenylpiperazine derivatives 242 129722-12-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • aripiprazole hydrate
  • aripiprazole
  • abilify
  • arpizol
  • pripiprazole
  • OPC-14597
An antipsychotic agent that is structurally related to piperazines and quinolones. It is a partial agonist of SEROTONIN RECEPTOR, 5-HT1A and DOPAMINE D2 RECEPTORS, where it also functions as a post-synaptic antagonist, and an antagonist of SEROTONIN RECEPTOR, 5-HT2A.
  • Molecular weight: 448.39
  • Formula: C23H27Cl2N3O2
  • CLOGP: 5.31
  • LIPINSKI: 1
  • HAC: 5
  • HDO: 1
  • TPSA: 44.81
  • ALOGS: -4.76
  • ROTB: 7

Drug dosage:

DoseUnitRoute
15 mg O
15 mg P
13.30 mg P

Approvals:

DateAgencyCompanyOrphan
June 4, 2004 EMA
Nov. 15, 2002 FDA OTSUKA

FDA Adverse Event Reporting System

scroll-->
MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Tardive dyskinesia 2408.66 33.99 498 12944 2013 3370404
Akathisia 1979.26 33.99 428 13014 2235 3370182
Weight increased 1845.46 33.99 663 12779 26077 3346340
Psychotic disorder 1456.59 33.99 424 13018 8310 3364107
Neuroleptic malignant syndrome 1281.37 33.99 332 13110 4109 3368308
Dystonia 1255.57 33.99 316 13126 3451 3368966
Off label use 1228.09 33.99 608 12834 53369 3319048
Extrapyramidal disorder 1207.89 33.99 306 13136 3437 3368980
Dyskinesia 971.99 33.99 298 13144 6987 3365430
Tremor 887.46 33.99 398 13044 27746 3344671
Maternal exposure during pregnancy 793.75 33.99 278 13164 9993 3362424
Mania 763.50 33.99 217 13225 3861 3368556
Delusion 724.29 33.99 202 13240 3343 3369074
Agitation 722.03 33.99 310 13132 19396 3353021
Parkinsonism 686.20 33.99 178 13264 2200 3370217
Restlessness 642.88 33.99 219 13223 7219 3365198
Insomnia 633.60 33.99 342 13100 35556 3336861
Suicide attempt 629.06 33.99 264 13178 15583 3356834
Completed suicide 609.91 33.99 318 13124 30796 3341621
Drug ineffective 598.88 33.99 515 12927 115575 3256842
Schizophrenia 598.55 33.99 164 13278 2530 3369887
Wrong technique in product usage process 588.65 33.99 256 13186 16495 3355922
Suicidal ideation 571.81 33.99 255 13187 17450 3354967
Anxiety 559.06 33.99 326 13116 39303 3333114
Sedation 544.24 33.99 184 13258 5917 3366500
Somnolence 518.70 33.99 289 13153 31915 3340502
Drug interaction 516.38 33.99 329 13113 46483 3325934
Treatment noncompliance 511.39 33.99 194 13248 8751 3363666
Aggression 493.18 33.99 202 13240 11183 3361234
Depression 482.44 33.99 297 13145 39473 3332944

Pharmacologic Action:

scroll-->
SourceCodeDescription
ATC N05AX12 NERVOUS SYSTEM
PSYCHOLEPTICS
ANTIPSYCHOTICS
Other antipsychotics
FDA EPC N0000175430 Atypical Antipsychotic
MeSH PA D014150 Antipsychotic Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014149 Tranquilizing Agents
CHEBI has role CHEBI:65191 second generation antipsychotic
CHEBI has role CHEBI:37955 H1-receptor antagonist
CHEBI has role CHEBI:35941 serotonergic agonist

Drug Use (View source of the data)

scroll-->
DiseaseRelationSNOMED_IDDOID
Mixed bipolar I disorder indication 16506000 DOID:3312
Schizophrenia indication 58214004
Bipolar disorder in remission indication 85248005
Bipolar affective disorder, current episode manic indication 191618007
Infantile autism indication 408857007 DOID:12849
Agitation associated with Bipolar Mania indication
Depression Treatment Adjunct indication
Agitation associated with Schizophrenia indication
Suicidal thoughts contraindication 6471006
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Senile dementia contraindication 15662003
Agranulocytosis contraindication 17182001 DOID:12987
Myocardial infarction contraindication 22298006 DOID:5844
Alzheimer's disease contraindication 26929004 DOID:10652
Orthostatic hypotension contraindication 28651003
Conduction disorder of the heart contraindication 44808001
Low blood pressure contraindication 45007003
Chronic heart failure contraindication 48447003
Hyperlipidemia contraindication 55822004 DOID:1168
Cerebrovascular disease contraindication 62914000 DOID:6713
Diabetes mellitus contraindication 73211009 DOID:9351
Hyperglycemia contraindication 80394007 DOID:4195
Leukopenia contraindication 84828003 DOID:615
Tardive dyskinesia contraindication 102449007
Seizure disorder contraindication 128613002 DOID:1826
Metabolic syndrome X contraindication 237602007 DOID:14221
Esophageal dysmotility contraindication 266434009 DOID:9192
Neutropenic disorder contraindication 303011007 DOID:1227
At risk for aspiration contraindication 371736008
Impaired cognition contraindication 386806002
Breastfeeding (mother) contraindication 413712001
Myocardial ischemia contraindication 414795007 DOID:3393
Obesity contraindication 414916001 DOID:9970

Acid dissociation constants calculated using MoKa v3.0.0

scroll-->
Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.84 Basic
pKa2 0.67 Basic

Orange Book patent data (new drug applications)

scroll-->
Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
10MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 7053092 Jan. 28, 2022 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
10MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 8642600 Jan. 28, 2022 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
10MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
15MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 7053092 Jan. 28, 2022 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
15MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 8642600 Jan. 28, 2022 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
15MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
20MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 7053092 Jan. 28, 2022 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
20MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 8642600 Jan. 28, 2022 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
20MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
2MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 7053092 Jan. 28, 2022 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
2MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 8642600 Jan. 28, 2022 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
2MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
30MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 7053092 Jan. 28, 2022 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
30MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 8642600 Jan. 28, 2022 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
30MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
5MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 7053092 Jan. 28, 2022 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
5MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 8642600 Jan. 28, 2022 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
5MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021713 Dec. 10, 2004 DISCN SOLUTION ORAL 7053092 Jan. 28, 2022 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021713 Dec. 10, 2004 DISCN SOLUTION ORAL 8642600 Jan. 28, 2022 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 7053092 Jan. 28, 2022 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 8642600 Jan. 28, 2022 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
15MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 7053092 Jan. 28, 2022 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
15MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 8642600 Jan. 28, 2022 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
15MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
20MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 7053092 Jan. 28, 2022 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
20MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 8642600 Jan. 28, 2022 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
30MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 7053092 Jan. 28, 2022 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
30MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 8642600 Jan. 28, 2022 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
10MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 7053092 Jan. 28, 2022 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
10MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
15MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 7053092 Jan. 28, 2022 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
15MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
20MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 7053092 Jan. 28, 2022 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
20MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
2MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 7053092 Jan. 28, 2022 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
2MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
30MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 7053092 Jan. 28, 2022 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
30MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
5MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 7053092 Jan. 28, 2022 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
5MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
10MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA, ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER, ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER, AND TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
15MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA, ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER, ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER, AND TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
20MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA, ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER, ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER, AND TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
2MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA, ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER, ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER, AND TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
30MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA, ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER, ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER, AND TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
5MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA, ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER, ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER, AND TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA, ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER, ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER, AND TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
15MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA, ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER, ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER, AND TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
20MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA, ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER, ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER, AND TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
30MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA, ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER, ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER, AND TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
10MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
10MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
10MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA
15MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
15MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
15MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA
20MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
20MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
20MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA
2MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
2MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
2MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA
30MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
30MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
30MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA
5MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
5MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
5MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338428 Aug. 6, 2023 TREATMENT OF SCHIZOPHRENIA
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338428 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8759351 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8759351 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338428 Aug. 6, 2023 TREATMENT OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338428 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8759351 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8759351 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338428 Aug. 6, 2023 TREATMENT OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338428 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8759351 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8759351 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338428 Aug. 6, 2023 TREATMENT OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338428 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8759351 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8759351 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
10MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
15MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
20MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
2MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
30MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
5MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021713 Dec. 10, 2004 DISCN SOLUTION ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
15MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
20MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
30MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
10MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
15MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
20MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
2MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
30MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
5MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
9.75MG/1.3ML (7.5MG/ML) ABILIFY OTSUKA N021866 Sept. 20, 2006 DISCN INJECTABLE INTRAMUSCULAR 7115587 July 21, 2024 TREATMENT OF SCHIZOPHRENIA
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8030313 Oct. 19, 2024 TREATMENT OF SCHIZOPHRENIA
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8030313 Oct. 19, 2024 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8030313 Oct. 19, 2024 TREATMENT OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8030313 Oct. 19, 2024 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8030313 Oct. 19, 2024 TREATMENT OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8030313 Oct. 19, 2024 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8030313 Oct. 19, 2024 TREATMENT OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8030313 Oct. 19, 2024 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338427 March 15, 2025 TREATMENT OF SCHIZOPHRENIA
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338427 March 15, 2025 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338427 March 15, 2025 TREATMENT OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338427 March 15, 2025 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338427 March 15, 2025 TREATMENT OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338427 March 15, 2025 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338427 March 15, 2025 TREATMENT OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338427 March 15, 2025 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
10MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
15MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
20MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
2MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
30MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
5MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
15MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
10MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
15MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
20MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
2MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
30MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
5MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
10MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
15MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
20MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
2MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
30MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
5MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021713 Dec. 10, 2004 DISCN SOLUTION ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
15MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
10MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
15MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
20MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
2MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
30MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
5MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
10MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9444503 Nov. 19, 2027 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
15MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9444503 Nov. 19, 2027 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
20MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9444503 Nov. 19, 2027 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
2MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9444503 Nov. 19, 2027 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
30MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9444503 Nov. 19, 2027 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
5MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9444503 Nov. 19, 2027 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
10MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8674825 April 9, 2029 METHOD OF USING A RECEIVER TO RECEIVE A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
15MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8674825 April 9, 2029 METHOD OF USING A RECEIVER TO RECEIVE A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
20MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8674825 April 9, 2029 METHOD OF USING A RECEIVER TO RECEIVE A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
2MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8674825 April 9, 2029 METHOD OF USING A RECEIVER TO RECEIVE A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
30MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8674825 April 9, 2029 METHOD OF USING A RECEIVER TO RECEIVE A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
5MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8674825 April 9, 2029 METHOD OF USING A RECEIVER TO RECEIVE A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
10MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8956288 July 6, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
15MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8956288 July 6, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
20MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8956288 July 6, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
2MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8956288 July 6, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
30MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8956288 July 6, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
5MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8956288 July 6, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
10MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8945005 Aug. 19, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
15MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8945005 Aug. 19, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
20MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8945005 Aug. 19, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
2MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8945005 Aug. 19, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
30MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8945005 Aug. 19, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
5MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8945005 Aug. 19, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
10MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8847766 March 29, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
15MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8847766 March 29, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
20MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8847766 March 29, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
2MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8847766 March 29, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
30MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8847766 March 29, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
5MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8847766 March 29, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
10MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8547248 Dec. 18, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
15MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8547248 Dec. 18, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
20MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8547248 Dec. 18, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
2MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8547248 Dec. 18, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
30MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8547248 Dec. 18, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
5MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8547248 Dec. 18, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
10MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9577864 Oct. 3, 2033 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
15MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9577864 Oct. 3, 2033 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
20MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9577864 Oct. 3, 2033 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
2MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9577864 Oct. 3, 2033 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
30MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9577864 Oct. 3, 2033 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
5MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9577864 Oct. 3, 2033 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
10MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9268909 Oct. 15, 2033 METHOD OF USING A LOGIC CIRCUIT TO STABILIZE BATTERY VOLTAGE SUPPLIED TO A SENSOR EMBEDDED WITH A TABLET AND THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
15MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9268909 Oct. 15, 2033 METHOD OF USING A LOGIC CIRCUIT TO STABILIZE BATTERY VOLTAGE SUPPLIED TO A SENSOR EMBEDDED WITH A TABLET AND THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
20MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9268909 Oct. 15, 2033 METHOD OF USING A LOGIC CIRCUIT TO STABILIZE BATTERY VOLTAGE SUPPLIED TO A SENSOR EMBEDDED WITH A TABLET AND THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
2MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9268909 Oct. 15, 2033 METHOD OF USING A LOGIC CIRCUIT TO STABILIZE BATTERY VOLTAGE SUPPLIED TO A SENSOR EMBEDDED WITH A TABLET AND THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
30MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9268909 Oct. 15, 2033 METHOD OF USING A LOGIC CIRCUIT TO STABILIZE BATTERY VOLTAGE SUPPLIED TO A SENSOR EMBEDDED WITH A TABLET AND THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
5MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9268909 Oct. 15, 2033 METHOD OF USING A LOGIC CIRCUIT TO STABILIZE BATTERY VOLTAGE SUPPLIED TO A SENSOR EMBEDDED WITH A TABLET AND THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
10MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9270503 Sept. 19, 2034 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
10MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9787511 Sept. 19, 2034 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
15MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9270503 Sept. 19, 2034 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
15MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9787511 Sept. 19, 2034 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
20MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9270503 Sept. 19, 2034 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
20MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9787511 Sept. 19, 2034 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
2MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9270503 Sept. 19, 2034 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
2MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9787511 Sept. 19, 2034 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
30MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9270503 Sept. 19, 2034 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
30MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9787511 Sept. 19, 2034 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
5MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9270503 Sept. 19, 2034 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
5MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9787511 Sept. 19, 2034 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT

Orange Book exclusivity data (new drug applications)

scroll-->
Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR July 27, 2020 NEW INDICATION OF MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER IN ADULTS
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR July 27, 2020 NEW INDICATION OF MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER IN ADULTS
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR July 27, 2020 NEW INDICATION OF MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER IN ADULTS
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR July 27, 2020 NEW INDICATION OF MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER IN ADULTS
10MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL July 27, 2020 NEW INDICATION OF MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER IN ADULTS
15MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL July 27, 2020 NEW INDICATION OF MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER IN ADULTS
20MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL July 27, 2020 NEW INDICATION OF MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER IN ADULTS
2MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL July 27, 2020 NEW INDICATION OF MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER IN ADULTS
30MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL July 27, 2020 NEW INDICATION OF MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER IN ADULTS
5MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL July 27, 2020 NEW INDICATION OF MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER IN ADULTS
10MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL Dec. 12, 2021 TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S
15MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL Dec. 12, 2021 TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S
20MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL Dec. 12, 2021 TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S
2MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL Dec. 12, 2021 TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S
30MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL Dec. 12, 2021 TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S
5MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL Dec. 12, 2021 TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S
1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021713 Dec. 10, 2004 DISCN SOLUTION ORAL Dec. 12, 2021 TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S
10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL Dec. 12, 2021 TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S
15MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL Dec. 12, 2021 TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S
20MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL Dec. 12, 2021 TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S
30MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL Dec. 12, 2021 TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S
9.75MG/1.3ML (7.5MG/ML) ABILIFY OTSUKA N021866 Sept. 20, 2006 DISCN INJECTABLE INTRAMUSCULAR Dec. 12, 2021 TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S

Bioactivity Summary:

scroll-->
TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
5-hydroxytryptamine receptor 2A GPCR ANTAGONIST Ki 7.90 WOMBAT-PK CHEMBL
5-hydroxytryptamine receptor 1A GPCR PARTIAL AGONIST Ki 8.15 WOMBAT-PK DRUG LABEL
D(2) dopamine receptor GPCR PARTIAL AGONIST Ki 8.71 WOMBAT-PK CHEMBL
D(4) dopamine receptor GPCR Ki 6.65 WOMBAT-PK
Sodium-dependent dopamine transporter Transporter Ki 5.49 PDSP
5-hydroxytryptamine receptor 5A GPCR Ki 5.91 PDSP
5-hydroxytryptamine receptor 3A Ion channel Ki 6.20 PDSP
5-hydroxytryptamine receptor 2B GPCR Ki 9.44 PDSP
Alpha-1B adrenergic receptor GPCR Ki 7.46 PDSP
5-hydroxytryptamine receptor 1E GPCR Ki 5.10 PDSP
D(1B) dopamine receptor GPCR Ki 5.68 PDSP
D(1A) dopamine receptor GPCR Ki 6.06 PDSP
Muscarinic acetylcholine receptor M3 GPCR Ki 5.33 PDSP
Alpha-2C adrenergic receptor GPCR Ki 7.42 PDSP
Alpha-2B adrenergic receptor GPCR Ki 6.99 PDSP
Muscarinic acetylcholine receptor M1 GPCR Ki 5.17 PDSP
Alpha-2A adrenergic receptor GPCR Ki 7.13 PDSP
Muscarinic acetylcholine receptor M5 GPCR Ki 5.63 PDSP
Beta-1 adrenergic receptor GPCR Ki 6.85 PDSP
Muscarinic acetylcholine receptor M4 GPCR Ki 5.82 PDSP
Muscarinic acetylcholine receptor M2 GPCR Ki 5.45 PDSP
D(3) dopamine receptor GPCR Ki 8.53 WOMBAT-PK
Alpha-1A adrenergic receptor GPCR Ki 7.24 WOMBAT-PK
5-hydroxytryptamine receptor 2C GPCR Ki 7.36 WOMBAT-PK
5-hydroxytryptamine receptor 1D GPCR Ki 7.20 WOMBAT-PK
Histamine H1 receptor GPCR Ki 7.21 WOMBAT-PK
5-hydroxytryptamine receptor 7 GPCR Ki 7.69 WOMBAT-PK
5-hydroxytryptamine receptor 6 GPCR Ki 6.51 WOMBAT-PK
Sodium-dependent serotonin transporter Transporter Ki 6.83 WOMBAT-PK
5-hydroxytryptamine receptor 1B GPCR Ki 6.10 WOMBAT-PK
Beta-2 adrenergic receptor GPCR Ki 6.79 PDSP
Sodium-dependent noradrenaline transporter Transporter Ki 5.68 PDSP
Multidrug resistance protein 1 Transporter IC50 6.11 CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel Ki 6.22 CHEMBL
D(1A) dopamine receptor GPCR Ki 9.10 CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 8.15 CHEMBL
Sodium-dependent serotonin transporter Transporter Ki 5.97 CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 9.40 CHEMBL
D(2) dopamine receptor GPCR Ki 9.10 CHEMBL
5-hydroxytryptamine receptor 2C GPCR IC50 7.59 CHEMBL
D(3) dopamine receptor GPCR IC50 7.42 CHEMBL
D(4) dopamine receptor GPCR ANTAGONIST Ki 7.30 IUPHAR
Histamine H1 receptor GPCR Ki 7 CHEMBL
5-hydroxytryptamine receptor 6 GPCR AGONIST Ki 6.80 IUPHAR
5-hydroxytryptamine receptor 7 GPCR AGONIST Ki 7.80 IUPHAR

External reference:

scroll-->
IDSource
34 IUPHAR_LIGAND_ID
4021367 VUID
N0000148786 NUI
C0299792 UMLSCUI
D01164 KEGG_DRUG
N0000010069 NDFRT
N0000148786 NDFRT
89013 RXNORM
d04825 MMSL
009852 NDDF
17034 MMSL
406784005 SNOMEDCT_US
406785006 SNOMEDCT_US
4021367 VANDF
231328 MMSL
82VFR53I78 UNII
7477 INN_ID
CHEMBL1112 ChEMBL_ID
60795 PUBCHEM_CID
DB01238 DRUGBANK_ID
D000068180 MESH_DESCRIPTOR_UI
CHEBI:31236 CHEBI

Pharmaceutical products:

scroll-->
ProductCategoryIngredientsNDCFormQuantityRoute MarketingLabel
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0093-7569 TABLET 5 mg ORAL ANDA 20 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0093-7580 TABLET 10 mg ORAL ANDA 20 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0093-7581 TABLET 15 mg ORAL ANDA 20 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0093-7582 TABLET 20 mg ORAL ANDA 20 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0093-7583 TABLET 30 mg ORAL ANDA 20 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0093-7613 TABLET 2 mg ORAL ANDA 20 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6509 TABLET 2 mg ORAL ANDA 20 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6510 TABLET 5 mg ORAL ANDA 20 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6511 TABLET 10 mg ORAL ANDA 20 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6512 TABLET 15 mg ORAL ANDA 20 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6513 TABLET 20 mg ORAL ANDA 20 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6514 TABLET 30 mg ORAL ANDA 20 sections
aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6655 TABLET 2 mg ORAL ANDA 19 sections
aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6656 TABLET 5 mg ORAL ANDA 19 sections
aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 13668-221 TABLET 30 mg ORAL ANDA 19 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 13811-679 TABLET 2 mg ORAL ANDA 20 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 13811-680 TABLET 5 mg ORAL ANDA 20 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 13811-681 TABLET 10 mg ORAL ANDA 20 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 13811-682 TABLET 15 mg ORAL ANDA 20 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 13811-683 TABLET 20 mg ORAL ANDA 20 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 13811-684 TABLET 30 mg ORAL ANDA 20 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 13811-692 TABLET, ORALLY DISINTEGRATING 10 mg ORAL ANDA 20 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 13811-693 TABLET, ORALLY DISINTEGRATING 15 mg ORAL ANDA 20 sections
ABILIFY HUMAN PRESCRIPTION DRUG LABEL 1 16590-323 TABLET 2 mg ORAL NDA 20 sections
ABILIFY HUMAN PRESCRIPTION DRUG LABEL 1 16590-745 TABLET 5 mg ORAL NDA 20 sections
ARIPIPRAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 16729-278 TABLET 2 mg ORAL ANDA 20 sections
ARIPIPRAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 16729-279 TABLET 5 mg ORAL ANDA 20 sections
ARIPIPRAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 16729-280 TABLET 10 mg ORAL ANDA 20 sections
ARIPIPRAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 16729-281 TABLET 15 mg ORAL ANDA 20 sections
ARIPIPRAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 16729-282 TABLET 20 mg ORAL ANDA 20 sections